Skip to content
BioAlmanacPeptide reference
Menu

Comparison

Semaglutide vs liraglutide: dose and weight loss

Both are approved GLP-1 receptor agonists for weight management, injected weekly and daily respectively. Same receptor, same class, one generation apart.

Both are GLP-1 receptor agonists and both hold approvals for weight management. Liraglutide came first; semaglutide is the later molecule, and the difference between them is mostly a difference in how long each stays in the body.

Searched the other way round, liraglutide vs semaglutide is the same comparison read from the other column. Which name comes first changes the order of the table and nothing in it.

That one property drives everything you would notice. Liraglutide's half-life supports a daily injection, semaglutide's a weekly one. Seven a week against one. That is the biggest practical gap between two drugs doing the same job.

The efficacy gap is real and it is not subtle. Across their trial programmes semaglutide produced roughly double the mean weight reduction, and a later head-to-head found the same thing.

Semaglutide vs liraglutide: dose and weight loss compared row by row
AttributeSemaglutideLiraglutide
Receptor targetsGLP-1GLP-1
Evidence levelApprovedApproved
Dosing frequencyOnce weeklyOnce daily
Half-lifeAbout 7 daysAbout 13 hours
Injections per yearAbout 52About 365
Mean weight reduction in trialsAround 15% at the higher doseAround 8%
Most common reported side effectsNausea, vomiting, constipationNausea, vomiting, diarrhoea

Things worth knowing

  • The side effects come from the same family for both, and both are dose-dependent. Neither turns out to be the gentler option once you titrate them to a comparable effect.
  • Liraglutide's shorter half-life cuts both ways. A bad reaction clears faster. A missed dose costs more.
  • Both are approved drugs, and the approved versions are prescribed and supervised. Neither trial programme tested anything that arrives in a vial labelled for research.

Full profile

Semaglutide

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.

Full profile

Liraglutide

The first GLP-1 analogue approved for weight loss. A daily injection, superseded by weekly semaglutide but still the best-documented compound in the class.

Questions

Is semaglutide or liraglutide more effective for weight loss?
Across their trial programmes semaglutide produced roughly double the mean weight reduction — around 15% at the higher dose against around 8% for liraglutide — and a later head-to-head comparison found the same direction of difference. Both figures come from trials of the approved, manufactured products. Neither programme tested anything that arrives in a vial labelled for research.
Is liraglutide vs semaglutide a different comparison?
No. It is the same pair in the other order, and the same table answers it. Which name is written first changes nothing about the half-lives, the schedules or the results either one reported.
How often is each one injected?
Semaglutide is injected once weekly and liraglutide once daily, which works out at about 52 injections a year against about 365. That follows from half-life: about seven days for semaglutide and about 13 hours for liraglutide.
Does one have milder side effects than the other?
The side effects reported for both come from the same family and both are dose-dependent — nausea and vomiting for either, with constipation more associated with semaglutide and diarrhoea with liraglutide. Neither turns out to be the gentler option once the two are titrated to a comparable effect.
Why does liraglutide need a daily injection?
Its half-life is about 13 hours, so the drug is substantially cleared within a day and the schedule has to replace it. Semaglutide was engineered to resist that clearance and lasts about seven days, which is what makes a weekly injection possible at all.

Related

Another comparisonRetatrutide vs semaglutideOne receptor against three, and a finished approval against a trial programme still running. The largest reported effect in the class, set beside the most established one.Another comparisonSemaglutide vs cagrilintideTwo different satiety pathways, usually discussed as a pair rather than a choice. One is an approved drug on its own; the other is mostly studied alongside it.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice.

Next

Where to take this